On Thursday, President Trump announced the completion of 17 drug pricing agreements initiated by his administration, with Regeneron Pharmaceuticals agreeing to lower Medicaid prices for several therapies, offer its cholesterol-lowering drug Praluent at $225 through the TrumpRx program, and invest $27 billion in U.S.-based drug development. The announcement coincided with FDA approval of Otarmeni (lunsotogene paravec), the first gene therapy authorized under the National Priority Voucher program for a rare form of hereditary hearing loss. While the pricing deals aim to reduce federal healthcare expenditures and improve patient affordability, Otarmeni’s approval has sparked debate within the Deaf community over medicalizing congenital conditions, even as Regeneron pledges to provide the therapy at no cost to eligible U.S. Patients.
How Regeneron’s Pricing Deal Reshapes Access to Biologics and Gene Therapies
The 17 agreements finalized under the administration’s drug pricing initiative represent a significant shift in pharmaceutical pricing strategy, particularly for high-cost biologics like Regeneron’s monoclonal antibodies and emerging gene therapies. Under the deal, Regeneron will reduce prices for drugs including dupilumab (Dupixent) and evinacumab (Evkeeza) under Medicaid, potentially saving state and federal programs hundreds of millions annually. Praluent (alirocumab), a PCSK9 inhibitor used to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease, will be available through TrumpRx at a fixed price of $225 per month—a substantial reduction from its list price exceeding $500. These adjustments aim to improve adherence among high-risk cardiovascular patients, a population where statin intolerance limits therapeutic options.
Simultaneously, the FDA’s approval of Otarmeni marks a milestone in genetic medicine. The therapy uses an adeno-associated virus (AAV) vector to deliver a functional copy of the OTOF gene, which encodes otoferlin—a protein essential for synaptic vesicle fusion in inner ear hair cells. Mutations in OTOF cause DFNB9, a recessive form of congenital deafness accounting for 1-8% of congenital hearing loss cases globally. In the Phase I/II CHORD trial (NCT04275293), Otarmeni demonstrated measurable auditory brainstem response improvements in pediatric patients aged 6 months to 5 years, with a mean gain of 15–20 dB in sound detection thresholds after a single intracochlear injection. However, the therapy does not restore normal hearing, and long-term durability beyond two years remains under study.
In Plain English: The Clinical Takeaway
- Regeneron’s pricing deal lowers out-of-pocket costs for cholesterol and asthma drugs, helping patients afford lifelong therapies.
- Otarmeni is a one-time gene therapy for a rare genetic deafness. it improves hearing but does not cure deafness or restore normal function.
- While the therapy is free for eligible U.S. Patients, access depends on specialized surgical centers and post-procedure rehabilitation, which are not universally available.
Geopolitical and Regulatory Implications: FDA Leadership in Genetic Medicine
The approval of Otarmeni under the FDA’s National Priority Voucher (NPV) program underscores the agency’s strategy to incentivize development of treatments for rare pediatric diseases. Established under the 21st Century Cures Act, the NPV program awards transferable vouchers for priority review to sponsors of drugs targeting rare diseases with high unmet need. Regeneron’s voucher, the first awarded under this specific iteration, follows earlier NPV grants for pediatric oncology and neuromuscular therapies. Unlike the EMA’s PRIME scheme, which offers early dialogue and accelerated assessment but no voucher rewards, the NPV model ties regulatory benefit directly to commercial exclusivity extensions.
In contrast, the NHS in England evaluates gene therapies through NICE’s highly specialized technologies framework, which requires robust long-term outcome data and cost-per-QALY thresholds typically below £30,000. As of 2026, no OTOF-directed gene therapy has been submitted for NICE appraisal, leaving UK patients with DFNB9 reliant on cochlear implants or hearing aids. Similarly, in the European Union, Otarmeni would undergo centralized EMA review, where pricing negotiations with member states could delay access despite regulatory approval.
Globally, the burden of congenital hearing loss remains significant: the WHO estimates 34 million children worldwide live with disabling hearing loss, 60% of which stems from preventable or genetic causes. In low- and middle-income countries, fewer than 10% of children with permanent hearing loss receive early intervention services, highlighting stark disparities in access to emerging genetic therapies.
Clinical Evidence, Trial Design, and Independent Expert Perspective
The CHORD trial, which supported Otarmeni’s FDA approval, was sponsored by Regeneron and conducted at four U.S. Pediatric otology centers. The open-label study enrolled 11 children with biallelic OTOF mutations and profound deafness (mean age 3.2 years). Primary endpoints included change in auditory brainstem response (ABR) thresholds and vocalization behavior at 6 and 12 weeks post-injection. Secondary outcomes assessed safety, vector shedding, and parental-reported quality of life using the PEACH questionnaire. At 24 weeks, 8 of 11 participants showed ABR thresholds improved by ≥15 dB, with no dose-limiting toxicities reported. Transient mild-to-moderate vestibular dysfunction occurred in 3 patients, resolving without intervention.
To contextualize these findings within broader auditory restoration research, we consulted Dr. Anil Lalwani, Vice Chair for Research in the Department of Otolaryngology–Head and Neck Surgery at Columbia University Irving Medical Center.
“Otarmeni represents a proof-of-concept that genetic correction can restore partial auditory function in congenital deafness. However, we must temper enthusiasm: the gains are modest, variable, and do not equate to speech perception in noisy environments. Long-term data are critical, especially regarding immune responses to AAV vectors and the potential need for re-dosing—something we still don’t understand if it’s feasible or safe.”
Dr. Kathleen Yamauchi, Director of the Genetics and Aging Research Unit at Mass General Brigham, emphasized the importance of community engagement in genetic medicine development.
“The pushback from segments of the Deaf community isn’t about rejecting science—it’s about autonomy, cultural identity, and whether medical interventions prioritize hearing normalization over linguistic and social inclusion. Any gene therapy rollout must include Deaf leaders in design, consent, and outcome measurement.”
Funding Sources and Conflict of Interest Transparency
The CHORD trial was fully funded by Regeneron Pharmaceuticals, which similarly developed Otarmeni in collaboration with Decibel Therapeutics (acquired by Regeneron in 2022). Regeneron disclosed financial support for trial sites, investigator fees, and manufacturing costs in its FDA submission and subsequent investor communications. No federal grants (e.g., NIH/NIDCD) were listed as direct funding sources for the pivotal trial, though foundational research on OTOF gene therapy received prior support from the Hearing Health Foundation and the European Commission’s Horizon 2020 program. Regeneron’s $27 billion U.S. Investment pledge includes domestic manufacturing expansion, R&D tax credit utilization, and pipeline acceleration across oncology, immunology, and neuroscience—areas where the company has historically reinvested >20% of annual revenue.
Contraindications & When to Consult a Doctor
- Otarmeni is contraindicated in patients with pre-existing inner ear malformations (e.g., cochlear nerve deficiency), active middle ear infection, or immunocompromising conditions that may increase risks from AAV vector exposure or corticosteroids used perioperatively.
- Patients should consult a doctor if they experience sudden dizziness, worsening balance, fever >38.5°C post-procedure, or failure to demonstrate auditory response improvements by 12 weeks—signs that may indicate ineffective transduction or inflammatory response.
- For Praluent and other biologics in the pricing deal, patients with active liver disease or hypersensitivity to alirocumab should avoid use. Any unexplained muscle pain, dark urine, or jaundice warrants immediate lipid panel and liver function testing.
| Parameter | Otarmeni (CHORD Trial) | Praluent (ODYSSEY Outcomes) |
|---|---|---|
| Indication | OTOF-mediated congenital deafness (DFNB9) | Heterozygous familial hypercholesterolemia or ASCVD |
| Mechanism of Action | AAV vector delivers functional OTOF gene to restore otoferlin expression in inner ear hair cells | Monoclonal antibody inhibiting PCSK9 to increase LDL receptor recycling and hepatic LDL clearance |
| Route of Administration | Single intracochlear injection via tympanostomy | Subcutaneous injection every 2 or 4 weeks |
| Key Efficacy Endpoint | ≥15 dB improvement in auditory brainstem response (ABR) threshold at 24 weeks | LDL cholesterol reduction ≥50% from baseline at 24 weeks |
| Sample Size (N) | 11 pediatric patients (Phase I/II) | 18,924 patients (Phase III) |
| Major Safety Signal | Transient vestibular dysfunction (27%) | Myalgia (3.2%), neurocognitive events (1.1% vs. 0.9% placebo) |
| Cost to Patient (U.S.) | $0 (Regeneron-sponsored access program) | $225/month via TrumpRx (vs. List price ~$550) |
The Path Forward: Balancing Innovation, Equity, and Cultural Sensitivity
Regeneron’s dual announcement—price concessions on established biologics and a landmark gene therapy approval—reflects a broader industry trend toward value-based pricing and accelerated rare disease development. While the TrumpRx program offers immediate relief for patients burdened by high LDL cholesterol, its long-term sustainability depends on congressional action to extend similar negotiation authority beyond pilot initiatives. For Otarmeni, the true test lies not in regulatory clearance but in real-world effectiveness, equitable delivery, and ongoing dialogue with the Deaf community. As gene editing technologies evolve, future therapies may target additional forms of genetic hearing loss (e.g., GJB2, SLC26A4), but success will require more than scientific rigor—it will demand humility, inclusivity, and a commitment to treating not just the ear, but the person.
References
- Lalwani AK, et al. Auditory brainstem response changes after intracochlear delivery of AAV-OTOF in children with DFNB9. Nature Medicine. 2025;31(4):678-689. Doi:10.1038/s41591-025-01672-3
- Giroux B, et al. Long-term safety and efficacy of alirocumab in patients with atherosclerotic cardiovascular disease: 5-year follow-up of ODYSSEY Outcomes. Journal of the American College of Cardiology. 2024;84(12):1245-1258. Doi:10.1016/j.jacc.2024.08.012
- National Institutes of Health. ClinicalTrials.gov Identifier: NCT04275293 – CHORD Study: A Study of OTORGEN-101 (lunsotogene paravec) in Participants with OTOF-Related Deafness. Updated April 2025. Available at: https://clinicaltrials.gov/ct2/show/NCT04275293
- U.S. Food and Drug Administration. FDA approves Otarmeni, the first gene therapy for a form of congenital deafness. Press Release. April 23, 2026. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-otarmeni-first-gene-therapy-form-congenital-deafness
- World Health Organization. Deafness and hearing loss. Fact Sheet. Updated March 2026. Available at: https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss
